Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imag...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.921667/full |
| _version_ | 1811231482799194112 |
|---|---|
| author | Ying Zhang Ying Zhang Ying Zhang Kazushi Numata Yuewu Du Shin Maeda |
| author_facet | Ying Zhang Ying Zhang Ying Zhang Kazushi Numata Yuewu Du Shin Maeda |
| author_sort | Ying Zhang |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis. |
| first_indexed | 2024-04-12T10:46:03Z |
| format | Article |
| id | doaj.art-d2c9660bdc064f30a997e2c399969761 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T10:46:03Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d2c9660bdc064f30a997e2c3999697612022-12-22T03:36:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.921667921667Contrast Agents for Hepatocellular Carcinoma Imaging: Value and ProgressionYing Zhang0Ying Zhang1Ying Zhang2Kazushi Numata3Yuewu Du4Shin Maeda5Department of Medical Ultrasound, Ningbo Medical Centre Li Huili Hospital, Ningbo, ChinaGastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanDepartment of Gastroenterology, Graduate School of Medicine, Yokohama City University, Yokohama, JapanGastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanDepartment of Medical Ultrasound, Ningbo Medical Centre Li Huili Hospital, Ningbo, ChinaDepartment of Gastroenterology, Graduate School of Medicine, Yokohama City University, Yokohama, JapanHepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis.https://www.frontiersin.org/articles/10.3389/fonc.2022.921667/fullultrasoundMRICECThepatocellular carcinoma (HCC)contrast media (CM) |
| spellingShingle | Ying Zhang Ying Zhang Ying Zhang Kazushi Numata Yuewu Du Shin Maeda Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression Frontiers in Oncology ultrasound MRI CECT hepatocellular carcinoma (HCC) contrast media (CM) |
| title | Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression |
| title_full | Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression |
| title_fullStr | Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression |
| title_full_unstemmed | Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression |
| title_short | Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression |
| title_sort | contrast agents for hepatocellular carcinoma imaging value and progression |
| topic | ultrasound MRI CECT hepatocellular carcinoma (HCC) contrast media (CM) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.921667/full |
| work_keys_str_mv | AT yingzhang contrastagentsforhepatocellularcarcinomaimagingvalueandprogression AT yingzhang contrastagentsforhepatocellularcarcinomaimagingvalueandprogression AT yingzhang contrastagentsforhepatocellularcarcinomaimagingvalueandprogression AT kazushinumata contrastagentsforhepatocellularcarcinomaimagingvalueandprogression AT yuewudu contrastagentsforhepatocellularcarcinomaimagingvalueandprogression AT shinmaeda contrastagentsforhepatocellularcarcinomaimagingvalueandprogression |